Modus Therapeutics AB: Modus Therapeutics is a Swedish-based biotechnology company dedicated to developing therapies that improve blood flow and oxygen transport. The company’s lead project, sevuparin, is currently in an ongoing Phase 2 study for the hospital-based treatment of painful crises in patients with Sickle Cell Disease (SCD). A second formulation, a subcutaneous formulation, will be a first-in class option for SCD patients and will allow dosing at home. By the end of 2018 we expect that the Phase II IV study will be fully enrolled and a Phase I PK study for the SC option will also be complete. Sevuparin has Orphan Drug Designation in the EU and US, Pediatric Rare Disease Designation in the US and patent protection through 2032.
Sankt Eriksgatan 117
Stockholm, SE 113 43

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.